Dr. Prasad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
510 S Kingshighway Blvd
Dept Radiology
Saint Louis, MO 63110Phone+1 314-362-7200Fax+1 314-747-4189
Education & Training
- MGM Medical College IndoreClass of 2001
Clinical Trials
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Current and Future Perspectives of PDL1 PET and SPECT Imaging.Indraja D Dev, Ameya D Puranik, Baljinder Singh, Vikas Prasad
Seminars in Nuclear Medicine. 2024-11-01 - 1 citationsNew horizon of radiopharmaceuticals in management of neuroendocrine tumors.Adeel Haq, Sampanna Rayamajhi, Maria Rosana Ponisio, Vikas Prasad
Best Practice & Research. Clinical Endocrinology & Metabolism. 2023-09-01 - 19 citationsSafety and Survival Outcomes ofLu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with PriorRa treatment: T...Kambiz Rahbar, Markus Essler, Kim M Pabst, Matthias Eiber, Christian la Fougère
Journal of Nuclear Medicine. 2023-04-01
Press Mentions
- Dosimetry Key in Lu-177 Cancer TherapyFebruary 5th, 2025
- Kromek Enters Agreement with Siemens Healthineers, Posts Q1 ResultsJanuary 30th, 2025
- Is Herpes Infection Protective in Early Alzheimer’s Disease Patients?January 24th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: